ABSTRACT
Objectives Use of Personal Protective Equipment (PPE) has been central to controlling spread of SARS-CoV2. Here we quantify the environmental impact of PPE distributed for use by the health and social care system in England, and model strategies for mitigating the environmental impact.
Methods Life cycle assessment was used to determine environmental impacts of PPE distributed to health and social care in England during the first six months of the COVID-19 pandemic. The base scenario assumed all products were single-use and disposed of via clinical waste. Scenario modelling was used to determine the effect of environmental mitigation strategies; 1) eliminating international travel during supply, 2) eliminating glove use 3) reusing gowns and face shields, 4) maximal recycling.
Results The carbon footprint of PPE distributed during the study period totalled 106,478 tonnes CO2e, with greatest contributions from gloves, aprons, face shields, and Type IIR surgical masks. The estimated damage to human health was 239 DALYs (disability adjusted life years), impact on ecosystems was 0.47 species.year (loss of local species per year), and impact on resource depletion was costed at US $ 12.7 (GBP £ 9.3) million.
Scenario modelling indicated UK manufacture would have reduced the carbon footprint by 12%, eliminating gloves by 45%, reusing gowns and gloves by 10%, and maximal recycling by 35%. A combination of strategies may have reduced carbon footprint by 75% compared with the base scenario, and saved an estimated 183 DALYS, 0.34 species.year, and US $ 7.4 (GBP £ 5.4) million due to resource depletion.
Conclusions The environmental impact of PPE is large and could be reduced through domestic manufacture, rationalising glove use, using reusables where possible, and optimising waste management.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
None to declare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required- this study did not involve any patients or healthcare staff.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Supporting data is available in supplementary files
